Literature DB >> 17033687

Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain.

Nathalie Ginovart1, Matthaeus Willeit, Pablo Rusjan, Ariel Graff, Peter M Bloomfield, Sylvain Houle, Shitij Kapur, Alan A Wilson.   

Abstract

The kinetic modeling of [11C]-(+)-PHNO binding to the dopamine D2/3 receptors in six human volunteers using positron emission tomography (PET) is described. [11C]-(+)-PHNO is the first agonist radioligand for the D2/3 in humans and as expected showed high uptake in caudate, putamen, globus pallidus (GP) and ventral striatum, and low uptake in cerebellum. A two-tissue compartment model (2CM) with four parameters was necessary to adequately fit time-activity data in all regions. Although a 2CM provided an excellent estimation of total distribution volumes, which were highly correlated with those obtained with the invasive Logan approach, it provided a poor identification of the k3/k4 ratios. Coupling K1/k2 between brain regions (Method C) or fixing K1/k2 to the value obtained in cerebellum (Method D) enabled more stable estimates of k3/k4 as compared with an unconstrained 2CM. The k3/k4 obtained with Method D ranged from 0.12+/-0.03 in cerebellum to 3.93+/-0.77 in GP and were similar to those obtained when coupling K1/k2. Binding potentials (BPs) obtained using the simplified reference tissue model (BP(SRTM)) ranged from 2.08+/-0.34 in caudate to 3.55+/-0.78 in GP and were highly correlated with k3/k4 estimates obtained with Method D (r=0.98). However, BP(SRTM) were 11%+/-5% lower than values obtained with Method D. BPs derived using the noninvasive Logan approach were slightly lower but not significantly different than BP(SRTM). This study demonstrates that [11C]-(+)-PHNO can be used for the quantitative measurement of D2/3 densities and should enable further studies of potential D2/3 dysregulation in several important psychiatric and neurologic illnesses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033687     DOI: 10.1038/sj.jcbfm.9600411

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  47 in total

1.  Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Authors:  David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

2.  Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO.

Authors:  Fernando Caravaggio; Jun Ku Chung; Philip Gerretsen; Gagan Fervaha; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Alan Wilson; Ariel Graff-Guerrero
Journal:  Soc Neurosci       Date:  2016-02-29       Impact factor: 2.083

3.  Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry.

Authors:  Fernando Caravaggio; Enzo Scifo; Etienne L Sibille; Sergio E Hernandez-Da Mota; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal:  Exp Eye Res       Date:  2018-06-05       Impact factor: 3.467

4.  Measurement error analysis for the determination of dopamine D(2) receptor occupancy using the agonist radioligand [(11)C]MNPA.

Authors:  Miho Shidahara; Hiroshi Ito; Tatsui Otsuka; Yoko Ikoma; Ryosuke Arakawa; Fumitoshi Kodaka; Chie Seki; Harumasa Takano; Hidehiko Takahashi; Federico E Turkheimer; Yuichi Kimura; Iwao Kanno; Tetsuya Suhara
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-16       Impact factor: 6.200

5.  Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO.

Authors:  Doris E Payer; Arian Behzadi; Stephen J Kish; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; Junchao Tong; Peter Selby; Tony P George; Tina McCluskey; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2013-08-07       Impact factor: 7.853

6.  DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum.

Authors:  Mikaeel Valli; Sang Soo Cho; Mario Masellis; Robert Chen; Pablo Rusjan; Jinhee Kim; Yuko Koshimori; Alexander Mihaescu; Antonio P Strafella
Journal:  Mol Neurobiol       Date:  2019-03-08       Impact factor: 5.590

Review 7.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

8.  Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand.

Authors:  Nicholas Seneca; Mette Skinbjerg; Sami S Zoghbi; Jeih-San Liow; Robert L Gladding; Jinsoo Hong; Pavitra Kannan; Edward Tuan; David R Sibley; Christer Halldin; Victor W Pike; Robert B Innis
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

9.  Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding.

Authors:  Alice Egerton; Ella Hirani; Rabia Ahmad; David R Turton; Diana Brickute; Lula Rosso; Oliver D Howes; Sajinder K Luthra; Paul M Grasby
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

10.  Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Authors:  Ariel Graff-Guerrero; Matthaeus Willeit; Nathalie Ginovart; David Mamo; Romina Mizrahi; Pablo Rusjan; Irina Vitcu; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.